清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 3407: Anti-tumor activity of tepotinib in orthotopic models of lung cancer patient-derived brain metastases with MET amplification

克里唑蒂尼 医学 肺癌 癌症研究 内科学 癌症 肿瘤科 药理学 恶性胸腔积液
作者
Manja Friese‐Hamim,Anderson Clark,Lindsey Crowley,Christof Reusch,Olga Bogatyrova,Claudia Wilm,Hong Zhang,Timothy Crandall,Jing Lin,Jianguo Ma,David Bachner,Jürgen Schmidt,Martin Schaefer,Christopher Stroh
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:80 (16_Supplement): 3407-3407 被引量:1
标识
DOI:10.1158/1538-7445.am2020-3407
摘要

Abstract Background Patients with advanced non-small cell lung cancer (NSCLC) harboring oncogenic MET alterations, such as MET exon 14 skipping or MET amplification (MET amp), benefit from MET tyrosine kinase inhibitor (TKI) treatment. Brain metastases are common in patients with advanced NSCLC. In preclinical studies in rats, tepotinib had relatively high binding to brain tissue (fu br=0.4%, fu pl=4%) and free tepotinib concentrations in brain were 25% of the concentrations found in plasma (Kp u,u=0.25). In this study we investigated the efficacy of the MET TKIs tepotinib, capmatinib, savolitinib and crizotinib in mice implanted orthotopically with MET-dependent tumor explants derived from human NSCLC brain metastases. Methods The antitumor activity of tepotinib (30 mg/kg qd) was investigated in a screen of 21 subcutaneous lung cancer patient-derived xenograft (PDX) models of brain metastases grown in NOD-SCID mice (n=1/model). 20 of these tumors were retrospectively analyzed for cancer-specific mutations, gene copy number (GCN) and gene expression by Nanostring. 2 responding models, both found to harbor MET amp, were tested again subcutaneously in NOD-SCID mice treated with vehicle or tepotinib (125 mg/kg qd; n=5). Both models were orthotopically implanted into brains of NOD-SCID mice and tumor growth was monitored by MRI. Established tumors were treated with MET TKIs (n=10) tepotinib (125 mg/kg qd), capmatinib (30 mg/kg bid), savolitinib (60 mg/kg qd) or crizotinib (50 mg/kg qd). Results 2 of 21 subcutaneous PDX tumors (LU5406 and LU5349) regressed in response to tepotinib treatment. When implanted subcutaneously again into mice, both models regressed completely upon treatment with tepotinib. Molecular profiles revealed that these were the only tumors of the 20 models investigated by Nanostring that had MET amp (high-level increase in MET GCN of >10). Both models grew orthotopically when implanted into brains of mice. Contrast-weighted MRI indicated regions with intact and disrupted blood–brain barrier (BBB) in all implanted tumors. Tumor regression of orthotopic LU5406 tumors was observed with all MET TKIs (% median tumor volume changes [%TV]: tepotinib, –63%; capmatinib, –24%; savolitinib, –38%; crizotinib, –27%). In the orthotopic LU5349 tumors, treatment with crizotinib or savolitinib led to growth inhibition (%TV: +88% and –13%, respectively), whereas tepotinib and capmatinib induced tumor regression (%TV: –84% and –63%, respectively). Conclusions The heterogenous pattern of regions with intact and disrupted BBB in the orthotopic brain metastases models is thought to mirror the clinical situation. Tepotinib was efficacious in the two MET-driven orthotopic brain metastases PDX tumors characterized by pronounced tumor regression and may be relevant to patients with brain metastases. Relationships between efficacy and BBB leakiness will be discussed. Citation Format: Manja Friese-Hamim, Anderson Clark, Lindsey Crowley, Christof Reusch, Olga Bogatyrova, Claudia Wilm, Hong Zhang, Timothy Crandall, Jing Lin, Jianguo Ma, David Bachner, Jürgen Schmidt, Martin Schaefer, Christopher Stroh. Anti-tumor activity of tepotinib in orthotopic models of lung cancer patient-derived brain metastases with MET amplification [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3407.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风中的世平完成签到,获得积分10
2秒前
Aman完成签到,获得积分10
2秒前
懒得起名字完成签到 ,获得积分10
7秒前
温暖的胜完成签到,获得积分10
13秒前
无悔完成签到 ,获得积分0
26秒前
纯真的雁凡完成签到,获得积分10
28秒前
柔弱的铅笔完成签到,获得积分10
30秒前
Tracy发布了新的文献求助10
36秒前
41秒前
顺利夏云完成签到,获得积分10
54秒前
xingsixs发布了新的文献求助10
55秒前
Tracy完成签到,获得积分10
1分钟前
zwlei完成签到,获得积分10
1分钟前
腼腆的雪珊完成签到,获得积分10
1分钟前
热情的衬衫完成签到,获得积分10
1分钟前
xingsixs完成签到,获得积分10
1分钟前
危机的白凡完成签到,获得积分10
1分钟前
徐伟业完成签到 ,获得积分10
1分钟前
RetchieLi完成签到,获得积分10
1分钟前
1分钟前
无限幻枫发布了新的文献求助10
1分钟前
眼睛大的向彤完成签到,获得积分10
1分钟前
俭朴映寒完成签到,获得积分10
1分钟前
汉堡包的应助被bluemoon采纳,获得10
1分钟前
1分钟前
王磊磊0811发布了新的文献求助10
2分钟前
害羞傲安完成签到,获得积分10
2分钟前
外向夜阑完成签到,获得积分10
2分钟前
LINDENG2004完成签到 ,获得积分10
2分钟前
年轻千萍完成签到,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
简单的不平完成签到,获得积分10
2分钟前
一个爱打乒乓球的彪完成签到 ,获得积分10
3分钟前
单身的涫完成签到,获得积分10
3分钟前
闪闪小凡完成签到,获得积分10
3分钟前
孝顺的冰姬完成签到,获得积分10
3分钟前
拼搏愚志完成签到,获得积分10
3分钟前
田田完成签到 ,获得积分10
3分钟前
无情幻巧完成签到,获得积分10
3分钟前
Lucas的应助被科研通管家采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370